Treatment for Patients With Non-Myeloid Malignancies Receiving Chemotherapy
Status:
Completed
Trial end date:
2004-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the time to hematopoietic response (hemoglobin
correction to 12 g/dL or a greater than or equal to 2 g/dL increase from baseline) for
subjects randomized to receive darbepoetin alfa with a front load dosing regimen to those
receiving recombinant human erythropoietin (rHuEPO) with a weekly dose regimen during the
12-week comparative treatment period.